<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00697229</url>
  </required_header>
  <id_info>
    <org_study_id>208129/004</org_study_id>
    <nct_id>NCT00697229</nct_id>
  </id_info>
  <brief_title>Immunogenicity &amp; Reactogenicity of HBV-MPL Vaccine and Engerix™-B in Healthy Adults Following 2 Different Schedules</brief_title>
  <official_title>Study to Evaluate the Immunogenicity and Reactogenicity of GSK Biologicals' MPL-Adjuvanted Recombinant Hepatitis B Vaccine in Comparison With Those of Engerix™-B in Healthy Adult Volunteers Following 2 Different Schedules</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, immunogenicity and reactogenicity of
      MPL-adjuvanted recombinant hepatitis B vaccine in comparison with those of Engerix™-B in
      healthy adult volunteers following two different schedules: 0, 2 months and 0, 6 months
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the time of conduct of this study, the sponsor GlaxoSmithKline was known by its former
      name SmithKline Beecham
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1992</start_date>
  <completion_date type="Actual">December 1998</completion_date>
  <primary_completion_date type="Actual">May 1996</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-hepatitis B surface antigen (HBs) antibody concentrations</measure>
    <time_frame>One month after the full primary vaccination course and one month after the booster vaccination at 70 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-HBs antibody concentrations</measure>
    <time_frame>Months 1, 2, 3, 6, 12, 13, 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse experiences (SAE).</measure>
    <time_frame>Throughout the study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence and intensity of solicited local symptoms</measure>
    <time_frame>8-day follow-up after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence, intensity and relationship of solicited general symptoms</measure>
    <time_frame>8-day follow-up after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of unsolicited symptoms</measure>
    <time_frame>During the 30-day follow-up after vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive HBV-MPL vaccine in the primary schedule 0, 2 months and will receive a booster dose of HBV-MPL vaccine at 70 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive HBV-MPL vaccine in the primary schedule 0, 2 months and will receive a booster dose of Engerix™-B vaccine at 70 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Engerix™-B vaccine in the primary schedule 0, 2 months and will receive a booster dose of HBV-MPL vaccine at 70 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Engerix™-B vaccine in the primary schedule 0, 2 months and will receive a booster dose of Engerix™-B vaccine at 70 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive HBV-MPL vaccine in the primary schedule 0, 6 months and will receive a booster dose of HBV-MPL vaccine at 70 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive HBV-MPL vaccine in the primary schedule 0, 6 months and will receive a booster dose of Engerix™-B vaccine at 70 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Engerix™-B vaccine in the primary schedule 0, 6 months and will receive a booster dose of HBV-MPL vaccine at 70 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Engerix™-B vaccine in the primary schedule 0, 6 months and will receive a booster dose of Engerix™-B vaccine at 70 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Engerix™-B</intervention_name>
    <description>Intramuscular injection, 1 or 3 doses</description>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_label>Group G</arm_group_label>
    <arm_group_label>Group H</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HBV-MPL vaccine</intervention_name>
    <description>Intramuscular injection, 1 or 3 doses</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_label>Group H</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 18 and 40 years old.

          -  Written informed consent will have been obtained from the subjects.

          -  Good physical condition as established by physical examination and history taking at
             the time of entry.

          -  Female participants will avoid becoming pregnant during the study period and they will
             have been on a contraceptive program for at least 2 months before entry.

        Exclusion Criteria:

          -  Positive titres for anti hepatitis B antibodies.

          -  Any vaccination against hepatitis B in the past.

          -  Elevated serum liver enzymes.

          -  History of significant and persisting hematologic, hepatic, renal, cardiac or
             respiratory disease.

          -  Axillary temperature &gt; 37°C at the time of injection.

          -  Any acute disease at the moment of entry.

          -  Chronic alcohol consumption.

          -  Any chronic drug treatment, including any treatment with immunosuppressive drugs,
             which in the investigator's opinion, precludes inclusion into the study.

          -  History of allergic disease likely to be stimulated by any component of the vaccine.

          -  Administration of any other vaccine(s) or any immunoglobulin during the study period.

          -  Simultaneous participation in any other clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Wilrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2008</study_first_submitted>
  <study_first_submitted_qc>June 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2008</study_first_posted>
  <last_update_submitted>June 11, 2008</last_update_submitted>
  <last_update_submitted_qc>June 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2008</last_update_posted>
  <responsible_party>
    <name_title>Isabelle Harpigny</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>Hepatitis B</keyword>
  <keyword>Engerix™-B</keyword>
  <keyword>Recombinant hepatitis B vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

